Q-omics provides the consensus-scored STK38L profile across patient tissues and cancer cell-line models. STK38L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, STK38L is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, STK38L RNA expression shows 19,681 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LGG, KICH, and KIRP as cancer lineages where STK38L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK38L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK38L survival associations across molecular data types. STK38L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK38L RNA expression–survival associations across cancer types. High STK38L expression shows unfavorable associations in LGG, LUSC, PAAD, MESO and STAD, but favorable associations in KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for STK38L RNA expression.
This table summarizes STK38L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for STK38L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK38L shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, CHOL, LUSC and COAD. The KICH box plot shows higher STK38L RNA expression in normal versus tumor tissue (log2 FC = −1.420, t-test p < 0.001).
This table shows molecular features associated with STK38L in patient tissues and cancer cell lines. In patient samples, STK38L shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, STK38L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
